Our Global Heme Cell and Gene Therapy (CGT) Operations team is at the forefront of innovation, commercial strategy, and operational excellence, driving the evolution of the global, cross-functional, "vein to vein" business process for CASGEVY, the only CRISPR-based autologous gene therapy approved for people living with Sickle Cell Disease and Transfusion dependent beta thalassemia. As CASGEVY continues to scale across 9+ markets globally, the successful candidate will bring a strategic, analytical, and collaborative mindset, provide cross-functional leadership and drive alignment among international and US Heme Business Units, Manufacturing, Quality, and Technology teams involved in CASGEVY delivery.